| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| 50g |
|
||
| 100g |
|
||
| Other Sizes |
|
2-Furoic acid is an orally bioactive heterocyclic carboxylic acid acting as a human cathepsin K inhibitor and is effective in lowering both serum cholesterol and serum triglyceride levels significantly in rats with an elevation of HDL cholesterol level at 20 mg/kg/day orally.
| ln Vivo |
2-Furoic acid considerably lowers blood levels of triglycerides and cholesterol [2]. Moreover, ATP-dependent citrate lyase, acetyl-CoA synthetase, acyl-CoA cholesterol acyltransferase, sn-glycerol 3-phosphate acyltransferase, phosphatidyl phosphohydrolase, and heparin induction lipoprotein lipase activity are all decreased by 2-furoic acid in the liver and gut[2]. The LD50 of 2-furoic acid in mice was 250 mg/kg ip in an acute toxicity study [2].
|
|---|---|
| References | |
| Additional Infomation |
2-furoic acid is a furoic acid having the carboxylic acid group located at position 2. It has a role as an inhibitor, a human xenobiotic metabolite, a Saccharomyces cerevisiae metabolite, a plant metabolite and a bacterial xenobiotic metabolite. It is a conjugate acid of a 2-furoate.
2-Furoic acid has been reported in Phomopsis velata, Aspergillus stellatus, and other organisms with data available. See also: 2-Furoate (annotation moved to). |
| Molecular Formula |
C5H4O3
|
|---|---|
| Molecular Weight |
112.08
|
| Exact Mass |
112.016
|
| CAS # |
88-14-2
|
| Related CAS # |
2-Furoic acid-d3;40073-83-4
|
| PubChem CID |
6919
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
230-232 ºC
|
| Melting Point |
129-133 ºC
|
| Flash Point |
137 ºC
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.513
|
| LogP |
0.64
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
8
|
| Complexity |
99.8
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
SMNDYUVBFMFKNZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H4O3/c6-5(7)4-2-1-3-8-4/h1-3H,(H,6,7)
|
| Chemical Name |
2-Furancarboxylic acid
|
| Synonyms |
alpha-Furoic acid2-Furoic acid alpha-Furancarboxylic acidKyselina 2-furoova2 Furoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~892.22 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (22.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (22.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (22.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 8.9222 mL | 44.6110 mL | 89.2220 mL | |
| 5 mM | 1.7844 mL | 8.9222 mL | 17.8444 mL | |
| 10 mM | 0.8922 mL | 4.4611 mL | 8.9222 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02517957 | UNKNOWN STATUS | Drug: Furoic acid loperamide hydrochloride cream Drug: Mullite ointment Drug: 3% boric acid solution Drug: Zine oxide |
Eczema | Shanghai Yueyang Integrated Medicine Hospital | 2015-08 | Phase 2 |
| NCT01987908 | TERMINATEDWITH RESULTS | Drug: Aes-103 Other: Placebo |
Sickle Cell Disease | Baxalta now part of Shire | 2013-12-03 | Phase 2 |
| NCT01597401 | COMPLETED | Drug: Aes-103 Drug: Aes-103 Drug: Aes-103 |
Sickle Cell Disease | Baxalta now part of Shire | 2012-05-12 | Phase 1 |
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
